Madrigal Pharmaceuticals

Madrigal Pharmaceuticals Announces Positive Quality of Life Outcomes for Rezdiffra in NASH Treatment

CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has revealed promising patient-reported outcomes showing that Rezdiffra (resmetirom) significantly enhances health-related quality of life (HRQL) for individuals with nonalcoholic steatohepatitis (NASH) with …

Madrigal Pharmaceuticals Announces Positive Quality of Life Outcomes for Rezdiffra in NASH Treatment Read More